1254. Prospective, open-label trial to evaluate efficacy of lyophilized fecal microbiota transplantation for treatment of recurrent C. difficile infection 
Session: Poster Abstract Session: C. difficile: From the Bench to Bedside
Friday, October 6, 2017
Room: Poster Hall CD
 

Background:  Fecal microbiota transplantation (FMT) has shown to be effective for recurrent Clostridium difficile infection (rCDI). However, significant laboratory costs for donor screening and a lack of suitable donors and laboratory facility have restricted the availability of the treatment. In order to expand access to FMT, we have investigated the efficacy of lyophilized FMT, comparing it to the published historical efficacy of frozen FMT in preventing further episodes of CDI in patients with a history of rCDI. This study was designed to be open-labeled to expedite and minimize costs associated with conducting a two-armed randomized controlled trial, given that the efficacy of frozen FMT is known to be 85%. Additionally, using lyophilized FMT offers two major advantages: 1) its prolonged shelf life reduces cost because fewer donors need to be screened; and 2) it can be transported without freezing.

Methods:  This is an open-labeled, prospective study involving 50 patients with a history of 2 or more rCDI who have failed at least 1 course of tapered vancomycin therapy. Eligible patients received 2 lyophilized FMT via retention enema within 8 days of each treatment and were followed for 13 weeks post last FMT to determine efficacy and safety of FMT.

Results:  The efficacy of lyophilized FMTs in preventing further episodes of CDI in patients with rCDI was 80%. The adverse events associated with lyophilized FMT were similar to frozen FMT.

Conclusion: Lyophilized FMT in treating rCDI showed similar efficacy and safety to frozen FMT. Lyophilized FMT appears to be promising in preventing further episode of CDI and increasing accessibility for patients with rCDI.

Peyman Goldeh, B.Eng1, Peter Kim, PhD2, Salaheddin Abouanaser, MD, FRCPC3, Eric Partlow, MD, FRCPC4, Patricia Beckett, RN3, Catherine Onishi, MLT3, Marek Smieja, MD, PhD5 and Christine Lee, MD, FRCPC6, (1)Vancouver Island Health Authority, Victoria, BC, Canada, (2)Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, (3)St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, (4)Vancouver Island Health Authority, Victoria, ON, Canada, (5)St. Joseph's Healthcare/McMaster University, Hamilton, ON, Canada, (6)Pathology and Laboratory Medicine, University of British Columbia, Victoria, BC, Canada

Disclosures:

P. Goldeh, None

P. Kim, None

S. Abouanaser, None

E. Partlow, None

P. Beckett, None

C. Onishi, None

M. Smieja, None

C. Lee, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.